Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Liabilities: 2022-2025

Historic Total Liabilities for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $146.7 million.

  • Centessa Pharmaceuticals' Total Liabilities rose 32.69% to $146.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.7 million, marking a year-over-year increase of 32.69%. This contributed to the annual value of $175.3 million for FY2024, which is 41.33% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Total Liabilities of $146.7 million as of Q3 2025, which was down 0.33% from $147.2 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Total Liabilities registered a high of $175.3 million during Q4 2024, and its lowest value of $101.0 million during Q2 2022.
  • In the last 3 years, Centessa Pharmaceuticals' Total Liabilities had a median value of $118.0 million in 2023 and averaged $128.6 million.
  • Over the last 5 years, Centessa Pharmaceuticals' Total Liabilities had its largest YoY gain of 41.33% in 2024, and its largest YoY loss of 6.27% in 2024.
  • Quarterly analysis of 4 years shows Centessa Pharmaceuticals' Total Liabilities stood at $108.1 million in 2022, then increased by 14.67% to $124.0 million in 2023, then surged by 41.33% to $175.3 million in 2024, then soared by 32.69% to $146.7 million in 2025.
  • Its Total Liabilities was $146.7 million in Q3 2025, compared to $147.2 million in Q2 2025 and $141.6 million in Q1 2025.